Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Experimental RNAi02:15

Experimental RNAi

6.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.1K
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

686
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
686
Tumor Immunotherapy01:27

Tumor Immunotherapy

491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

858
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
858
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effectiveness of Computerized Cognitive Remediation Therapy on Executive Functions and Clinical Symptoms in Children and Adolescents With ADHD: A Meta-Analysis of Randomized Controlled Trials.

Alpha psychiatry·2026
Same author

GIPC1 governed ferroptosis by regulating DECR1-modulating lipid homeostasis during dilated cardiomyopathy (DCM).

Cell death and differentiation·2026
Same author

In Utero and Early-Life Exposure to Tobacco Smoke, Genetic Risk, and Chronic Obstructive Pulmonary Disease Incidence in Adulthood.

Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco·2026
Same author

KIRA6 restrains the generation of myeloid-derived suppressor cells and overcomes resistance to anti-PD-1 therapy.

Cell death & disease·2025
Same author

RBMS1 orchestrates cardiac hypertrophy by facilitating CTTN splice-switching and sarcomere dynamics.

EMBO molecular medicine·2025
Same author

Symptoms of depression in middle-aged and older adults with schizophrenia in Guangzhou, China: a cross-sectional study.

Frontiers in psychiatry·2025

Related Experiment Video

Updated: Jun 12, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K

RIG-I is an intracellular checkpoint that limits CD8+ T-cell antitumour immunity.

Xiaobing Duan1,2, Jiali Hu3, Yuncong Zhang3

  • 1Guangdong Provincial Key Laboratory of Tumour Interventional Diagnosis and Treatment, Zhuhai People's Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai, 519000, China. duanxb3@mail3.sysu.edu.cn.

EMBO Molecular Medicine
|September 25, 2024
PubMed
Summary

Retinoic acid-inducible gene I (RIG-I) acts as an intracellular checkpoint, suppressing CD8+ T-cell anti-tumor immunity. Targeting RIG-I may enhance cancer immunotherapy responses.

Keywords:
AKT/Glycolysis Signalling PathwayCD8+ T cellsImmune CheckpointImmunotherapyRIG-I

More Related Videos

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K
Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE
12:43

Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE

Published on: July 29, 2014

12.1K

Related Experiment Videos

Last Updated: Jun 12, 2025

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
07:36

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice

Published on: June 12, 2021

6.4K
Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses
10:13

Tailoring In Vivo Cytotoxicity Assays to Study Immunodominance in Tumor-specific CD8+ T Cell Responses

Published on: May 6, 2019

8.9K
Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE
12:43

Monitoring Activation of the Antiviral Pattern Recognition Receptors RIG-I And PKR By Limited Protease Digestion and Native PAGE

Published on: July 29, 2014

12.1K

Area of Science:

  • Immunology
  • Cancer Biology
  • Molecular Biology

Background:

  • Retinoic acid-inducible gene I (RIG-I) is a pattern recognition receptor crucial for innate immunity.
  • Its specific role in adaptive immunity, particularly CD8+ T-cell mediated anti-tumor responses, is not well understood.

Purpose of the Study:

  • To investigate the function of RIG-I in CD8+ T-cell anti-tumor immunity.
  • To determine if RIG-I acts as a therapeutic target for cancer immunotherapy.

Main Methods:

  • Analysis of RIG-I expression in tumor-infiltrating CD8+ T cells.
  • Investigation of RIG-I's downstream signaling pathways, including AKT/glycolysis.
  • Evaluation of RIG-I knockout and inhibition strategies in preclinical tumor models.
  • Assessment of combination therapy with PD-1 blockade.

Main Results:

  • RIG-I is upregulated in tumor-infiltrating CD8+ T cells, negatively regulating their function.
  • RIG-I upregulation is induced by activated T cells and inhibits the AKT/glycolysis pathway.
  • RIG-I knockout enhances adoptively transferred T-cell efficacy against solid tumors.
  • RIG-I inhibition improves responses to PD-1 blockade immunotherapy.

Conclusions:

  • RIG-I functions as an intracellular checkpoint that limits CD8+ T-cell anti-tumor immunity.
  • Targeting RIG-I represents a promising strategy to enhance cancer immunotherapy, potentially in combination with immune checkpoint inhibitors.